We are live on
!
Find out more
Iovance Biotherapeutics
IOVA
IOVA
285 hedge funds and large institutions have $943M invested in Iovance Biotherapeutics in 2026 Q1 according to their latest regulatory filings, with 64 funds opening new positions, 121 increasing their positions, 58 reducing their positions, and 39 closing their positions.
New
Increased
Maintained
Reduced
Closed
109% more repeat investments, than reductions
Existing positions increased: 121 | Existing positions reduced: 58
64% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 39
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
32% more capital invested
Capital invested by funds: $715M → $943M (+$228M)
8% more funds holding
Funds holding: 264 → 285 (+21)
4% more call options, than puts
Call options by funds: $15.1M | Put options by funds: $14.6M
0.6% less ownership
Funds ownership: 65.9% → 65.3% (-0.6%)
Holders
285
Holders Change
+21
Holders Change %
+7.95%
% of All Funds
3.51%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
64
Increased
121
Reduced
58
Closed
39
Calls
$15.1M
Puts
$14.6M
Net Calls
+$562K
Net Calls Change
-$5.54M
Top Buyers
| 1 |
Two Sigma Investments
New York
|
+$29.7M |
| 2 |
D.E. Shaw & Co
New York
|
+$13.4M |
| 3 |
Millennium Management
New York
|
+$9.05M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$7.53M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$7.29M |
Top Sellers
| 1 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
-$20.8M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$18.5M |
| 3 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
-$11.1M |
| 4 |
Morgan Stanley
New York
|
-$9.57M |
| 5 |
State Street
Boston,
Massachusetts
|
-$8.68M |
